Flagship's creative approach to finding the next big idea in biopharma

Avak Kahvejian, partner at Flagship Pioneering, a company that conceives, creates and launches bioplatform companies like Moderna, discusses its latest venture, ProFound Therapeutics.

By Alexandra Pecci • June 1, 2022

Cell and gene therapy advances coming fast and furious

A peek into R&D at the Mass General Brigham network reveals up-and-coming treatments pushing the boundaries of what’s possible in medicine.

By Kelly Bilodeau • June 1, 2022

Explore the Trendline➔

Big Pharma Business Strategies

Large pharmas are consistently tasked with the goal of growth. But in recent years, the upward trajectory has been littered with new hurdles. 

By PharmaVoice staff

First 90 Days: Sosei Heptares’ Chris Cargill

The company’s new CEO is looking to drive growth through collaboration and transparency.

By Kim Ribbink • May 31, 2022

Woman of the Week: Ferring Pharmaceutical's Araz Raoof

Growing up in Iraqi Kurdistan, Raoof says a 'lethal combination' of books and strong women paved her way into STEM.

By Taren Grom • May 25, 2022

First 90 Days: Syneos Health’s Michelle Keefe

The newly minted CEO is leaning on her 30 years of experience leading high-performance teams to make her mark at Syneos.

By Taren Grom • May 23, 2022

Woman of the Week: Sparrow Pharmaceuticals' Jamie MacPherson

The vice president of regulatory affairs and quality on embracing leadership challenges in drug development.

By Taren Grom • May 18, 2022

Jumping into pharma with big plans at a small company

SpringWorks Therapeutics' chief medical officer on the ambition that drives him and his company to develop treatments for cancer patients.

By Alexandra Pecci • May 17, 2022

BriOri BioTech sets the stage for the comeback of Vioxx

With a topical pain-relieving ointment in development, the emerging biotech is aiming to give the tarnished NSAID a new life.

By Kelly Bilodeau • May 17, 2022

Biotech Spotlight: Graphite Bio seeks sickle cell cure with a next-gen approach

Using gene editing, CEO Josh Lehrer says the company is poised to ‘offer a cure’ to a long list of diseases.

By Michael Gibney • May 17, 2022

Are digital DCTs the answer for rare diseases?

How data from EHRs is helping to identify, diagnose and recruit patients to decentralized clinical trials.

By Kim Ribbink • May 16, 2022

After 40 years, researchers discover new frontiers in the fight against HIV

Medical advances in the last two decades may now provide scientists with the right toolbox to target the long-elusive virus.

By Karissa Waddick • May 16, 2022

With the shine of amyloid fading, tau is a rising star in Alzheimer's

The tau theory in Alzheimer's is being put to the test with phase 3 trial results due later this month from TauRx Pharmaceuticals.

By Michael Gibney • May 11, 2022

In the hot pharma talent market, execs battle these recruitment misconceptions

One of the top recruiting firms in life sciences weighs in on how companies can attract the next wave of rising stars.

By Meagan Parrish • May 11, 2022

FDA draft guidance may turn diversity in clinical trials from nice-to-have into a must-have

New guidance from the FDA will ‘up the ante’ for diversity considerations. Here’s how your company can prepare.

By Kelly Bilodeau • May 10, 2022

Where hope and uncertainty meet: A cutting-edge cancer developer's winding road

Replimune is on the precipice of a new kind of cancer treatment, but its CEO knows something about ambiguity.

By Alexandra Pecci • May 9, 2022

Biotech Spotlight: Everest Medicines takes aim at unmet needs in Asia

With a multi-pronged business strategy, Everest Medicines is positioning itself as a ‘rising force’ in Asian biotech.

By Taren Grom • May 9, 2022

Ultra-sensitive tests bring biomarkers into the drug development forefront

An agreement between the biomarker assay maker Quanterix and pharma giant Eli Lilly could help discover new ways to treat Alzheimer's.

By Michael Gibney • May 5, 2022

Woman of the Week: Amgen's Dr. Jane Parnes

As executive medical director, early development at Amgen, Dr. Jane Parnes has helped guide clinical research for upwards of 30 of the company’s investigational molecules, including the newly approved Tezspire for severe asthma — one of her career highlights.

By Taren Grom • May 4, 2022

Breaking new ground: Longhorn's trailblazing effort to develop a universal flu vaccine

After years of success with their diagnostic platform for COVID-19, tuberculosis and the flu, the family funded company is shifting priorities back to the vaccine market.

By Taren Grom , Karissa Waddick • May 4, 2022

From cancer survivor to clinical trial innovator

How Alicia Staley is using her insights as a three-time cancer survivor to drive clinical trial improvements at Medidata.

By Kelly Bilodeau • May 3, 2022

One company's failed drug is this company's 'jewel'

Dr. Thomas Bock, CEO of Notable, is helping the company develop a ‘new class’ of predictive precision medicines in oncology.

By Meagan Parrish • May 2, 2022

A nuclear threat spurs France's Medesis to advance radiation therapy

In the event of a nuclear event — intentional or accidental — rapid and widespread deployment of effective treatments is paramount.

By Kelly Bilodeau • May 2, 2022

How an open platform can shake up the drug development process

TetraScience’s Alan Millar shares why pharma is rethinking data integration in the race to be faster, better and more effective.

By Kim Ribbink • April 28, 2022

Woman of the Week: Gilead Science's Dr. Shanthi Ganeshan

As vice president of Global Regulatory Affairs, Oncology at Gilead, Ganeshan says there’s ‘never a dull moment’ in the quest to deliver therapies to patients.

By Taren Grom • April 27, 2022

Laura Randa's aim to break down mental healthcare barriers for disabled patients

Despite the proliferation of mental health apps, many aren’t accessible for people with disabilities. The CEO of Toivoa plans to change that.

By Alexandra Pecci • April 27, 2022